BioMarin Pharmaceutical Inc.
NASDAQ:BMRNBiotechnology
-$0.10 today
- Market cap
- $11.90B
- Beta
- 0.24
- P/E (TTM)
- 39.4
- EPS (TTM)
- $1.40
Volume 3.07M
Average 2.04M
BMRN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
BioMarin Pharmaceutical Inc.NASDAQ: BMRN
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development growth accelerates
Q3 FY2026 research & development of $180.53B rose 43986.6% year over year, ahead of the +19955.1% change in trailing-twelve-month research & development. Sequentially, it rose 87130.4% from the prior quarter. Over 3 fiscal years it compounded at +12.4% a year.
Context
- Research & development amounted to 28.6% of revenue in FY2025, up 2.4 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +43986.6% holds above the trailing-twelve-month pace of +19955.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 921.93M USD
- Year-over-year change
- +23.4%
- 4-year CAGR
- +10.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 921.93M | +23.4% |
| FY2024 | 2024-12-31 | 747.18M | +0.1% |
| FY2023 | 2023-12-31 | 746.77M | +15.0% |
| FY2022 | 2022-12-31 | 649.61M | +3.3% |
| FY2021 | 2021-12-31 | 628.79M | — |
Research & Development vs competitors
How BMRN compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +19955.1% is the highest of 11, against a peer median of +12.3%.
- Research & development amounts to 17.6% of revenue for BMRN, versus a peer median of 40.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $181.1B USD | +19955.1% | +12.4% | 17.6% | |
| LTM Sep 2026 | $4.25B USD | +6.5% | +12.2% | 32.7% | |
| LTM Jun 2026 | $1.51B USD | +30.1% | +14.5% | 31.4% | |
| LTM Sep 2026 | $923.16M USD | +4.7% | +3.2% | 96.2% | |
| LTM Jun 2026 | $860.85M USD | +30.4% | +24.7% | 75.7% | |
| LTM Mar 2026 | $770.95M USD | +12.5% | +2.0% | 115.2% | |
| LTM Jun 2026 | $530.96M USD | +12.1% | +6.1% | 74.5% | |
| LTM Jun 2026 | $433.31M USD | -14.7% | -11.3% | 43.0% | |
| LTM Sep 2026 | €274.3M EUR | -10.0% | -9.3% | 22.7% | |
| LTM Sep 2026 | $245.55M USD | +16.8% | -3.2% | 37.7% | |
| LTM Mar 2026 | $104.71M USD | +22.1% | +23.1% | 28.3% | |
| Peer median (excluding BMRN) | — | +12.3% | +4.7% | 40.3% | |
Competitors are the stored peer set for BMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.85B | 2.1B | 2.42B | 2.85B | 3.22B |
| Cost of Revenue | 470.52M | 503.02M | 532.06M | 580.24M | 736.83M |
| Gross Profit | 1.38B | 1.59B | 1.89B | 2.27B | 2.48B |
| Gross Margin | 74.5% | 76.0% | 78.0% | 79.7% | 77.1% |
| Research & Development | 628.79M | 649.61M | 746.77M | 747.18M | 921.93M |
| Selling, General & Admin | 759.4M | 823.2M | 892.4M | 1.01B | 1.28B |
| Operating Expenses | 1.46B | 1.43B | 1.7B | 1.79B | 1.95B |
| Depreciation & Amortization | 108.04M | 101.97M | 104.39M | 96.43M | 79.56M |
| EBITDA | 47.43M | 265.36M | 306.77M | 650.53M | 572.94M |
| EBITDA Margin | 2.6% | 12.7% | 12.7% | 22.8% | 17.8% |
| Operating Income | (82.34M) | 160.97M | 185.77M | 484.21M | 533.48M |
| Operating Margin | -4.5% | 7.7% | 7.7% | 17.0% | 16.6% |
| Interest Income | 10.48M | 18.03M | 58.34M | 74.88M | 74.9M |
| Interest Expense | 15.34M | 15.97M | 17.34M | 12.67M | 10.9M |
| Other Income / Expenses | 6.99M | (11.4M) | 2.79M | 57.55M | (51M) |
| Income Before Tax | (75.35M) | 149.58M | 188.56M | 541.76M | 482.48M |
| Pre-Tax Margin | -4.1% | 7.1% | 7.8% | 19.0% | 15.0% |
| Income Tax Expense | (11.27M) | 8.02M | 20.92M | 114.9M | 133.58M |
| Net Income | (64.08M) | 141.56M | 167.65M | 426.86M | 348.9M |
| Net Margin | -3.5% | 6.8% | 6.9% | 15.0% | 10.8% |
| EPS (Basic) | (0.35) | 0.76 | 0.89 | 2.25 | 1.82 |
| EPS (Diluted) | (0.35) | 0.75 | 0.88 | 2.21 | 1.80 |
| Weighted Avg Shares | 182.85M | 185.27M | 187.83M | 190.03M | 191.79M |
| Weighted Avg Shares (Diluted) | 182.85M | 188.96M | 191.6M | 196.71M | 197.39M |
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
Intrinsic Alpha fair value
Locked
Current Price
$61.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.